

ASCEPT Virtual Annual Scientific Meeting

29 NOV – 2 DEC 2021

20/20 Hindsight – creating a sustainable future for pharmacology and toxicology



#ASCEPT2021
www.asceptasm.com

Scientific program

Thank you to our meeting sponsors and supporters.

Principal sponsor



Major sponsors



Key sponsors



Networking sponsor



Poster sponsor



Meeting supporters



Society friends



Monday 29 November 2021 | 11.00am – 4.00 pm Australian Eastern Daylight Time (AEDT)

Pre-meeting Special Interest Group Workshops

11.00am – 1.00pm Morning workshops

Education Forum

Facilitator: Dr Angela Finch, UNSW Sydney

11.00am – 12.00pm Innovations in Education from across ASCEPT-Panel Discussion

This session will highlight innovative educational approaches that our members have developed to enhance the teaching of topics that reflect the diversity of pharmacology represented by our special interest groups.

Panelists: Dr Iris Lim, Bond University; Dr Nel Karunaratne, Dr Betty Exintaris, Dr Jennifer Irvine, Dr Sab Ventura, Monash University; Dr Angela Finch, Dr Nicole Jones, UNSW Sydney; Dr Ian Musgrave, University of Adelaide

12.00pm – 12.30pm Follow-up from challenges and adventures in hybrid teaching mid-year workshop

This session will invite participants to reflect on their experiences with hybrid (online and face to face) teaching and share success and/or failures of different approaches/projects they have tried.

12.30pm – 1.00pm Education Forum AGM

Drug Discovery workshop: Application of artificial intelligence and computational tools in drug discovery

Facilitators: Dr Katie Leach, Dr Michelle Halls and Assoc Prof Denise Wootten, Monash University

Supported by



Overview: This workshop is designed to introduce researchers to the core concepts in artificial intelligence (AI) and high-performance computing (HPC), the fundamentals to get started with using AI, and to provide examples of how these approaches can be utilised in pharmacological research and drug discovery.

11.00am – 12.10pm Deep Learning Workshop – Theory and Concepts

Chair: Dr Michelle Halls, Monash University

Presenters: Erika Choong and William Maclean from Monash DeepNeuron; a student-led non-profit engineering team that promote accessibility of AI and HPC.

12.10pm – 12.40pm Exploiting computational approaches to facilitate G protein-coupled receptor pharmacology and drug discovery.

Chair: Assoc Prof Denise Wootten, Monash University

Presenter: Alex Hauser, University of Copenhagen

12.40pm – 13.00pm Panel discussion/ Q&A

Moderator: Dr Katie Leach, Monash University

Panelists: Dr Lauren May, Ahn Nguyen, Monash University; William Maclean, Erika Choong, Ayden Khalil, Monash DeepNeuron

Pharmacogenomics workshop: No one and no disease gets left behind – progressing the clinical implementation of pharmacogenomics

Facilitator: Prof Andrew Somogyi, The University of Adelaide

11.05am – 11.35am Translating Pharmacogenomics in Mental Health Care

Assoc Prof Kathy Wu, St Vincent's Hospital

11.35am – 12.10pm U-PGx: Design and Netherlands Implementation

Assoc Prof Jesse Swen, Leiden University Medical Center, The Netherlands

12.10pm – 12.25pm Pharmacogenomic testing: Perception of clinical utility, and enablers and barriers to adoption in Australian hospitals

Dr Sophie Stocker, The University of Sydney

12.25pm – 12.40pm Closing the Loop: Pharmacogenetics in Australian Pharmacies

Mr Nicholas Haddrick, Honours student, The University of Canberra

12.40pm – 1.00pm AGM

2.00pm – 4.00pm Afternoon workshops

Careers workshop

Facilitators: Dr Betty Exintaris and Assoc Prof Barbara Kemp-Harper, Monash University

Student facilitators: David Nash, Jessica Lu, Abhipree Sharma, Nimna Perea, Monash University; Kinjal Patel, UNSW Sydney; Aili Langford, The University of Sydney

The purpose of this workshop will be to hear from professionals in education, industry, government and research who have transitioned from or stayed in research. The format will include individual presentations, a panel discussion and networking in breakout rooms. The speakers are:

- Ms Katie Martin, Policy Officer at the Australian Government Department of Health, Canberra
- Prof Mark Hutchinson, Director of the ARC Centre of Excellence for Nanoscale BioPhotonics, University of Adelaide
- Assoc Prof Tamara Paravicini, STEM College, RMIT University
- Dr Preet Chadha, Senior Medical Manager (Oncology), AstraZeneca

Clinical Pharmacology workshop:

To TDM or not to TDM, that is the question!

Chair: Assoc Prof Darren Roberts, St Vincent's Hospital; UNSW Sydney

2.00pm – 2.20pm **Principles to consider when deciding to apply TDM**
Assoc Prof Darren Roberts, St Vincent's Hospital; UNSW Sydney

2.20pm – 2.45pm **Linezolid – A role for TDM?**

Dr Vincent Seah, St Vincent's Hospital Sydney
Prof Debbie Marriott, St Vincent's Hospital Sydney
Prof Dario Cattaneo, L. Sacco University Hospital, Milano, Italy

2.45pm – 3.25pm **Interactive discussion groups**

Group 1: Inter-patient variability - What does the evidence indicate about inter-patient variability in linezolid pharmacokinetics? Does this justify TDM? What clinical scenarios are important to consider?

Group 2: ADRs - Are there pharmacokinetic predictors of linezolid adverse drug reactions? Does this justify TDM? What clinical scenarios are important to consider?

3.25pm – 4.00pm **Panel discussion: Other indications or considerations for TDM**

Tuesday 30 November 2021 | 12.00 – 5.40 pm Australian Eastern Daylight Time (AEDT)

-#abstract number

12.00 – 12.46

Meeting opening and opening keynote presentation

Assoc Prof Danijela Gnjidic, ASCEPT President
Dr Nicola Smith, ASCEPT Acting SAC Chair
Assoc Prof Barbara Kemp-Harper, Tribute to Liz Davis

Supported by

Bb Bellberry Limited
supporting research and ethics

Chair: Prof Kevin Pflieger, University of Western Australia

REMAP-CAP: An adaptive platform trial evaluating multiple candidate treatments for severe COVID-19 -#100

Prof Steve Webb, Royal Perth Hospital

12.48 – 1.08

Concurrent session

Meet the speaker discussion with Prof Steve Webb

Facilitator: Prof Kevin Pflieger, University of Western Australia

(20 pre-registered participants)

Time to view ePosters and visit the sponsors' portal

1.08 – 1.14

Break

Supported by



1.15 – 2.15

Concurrent 1 symposium sessions

Symposium 1: Targeting GPCRs to treat cardiometabolic disease

Supported by



MONASH
INSTITUTE OF
PHARMACEUTICAL
SCIENCES

Symposium 2: How do we authentically skill our graduates?

Symposium 3: Pharmacological development of new medicines for heart failure

Supported by



Co-chairs: Assoc Prof Denise Wootten and Prof Chrisan S Samuel, Monash University

Co-chairs: Dr Angela Finch and Ms Meg Mouat, UNSW Sydney

Co-chairs: Dr Louise See Hoe, The University of Queensland and The Prince Charles Hospital and Dr Miles De Blasio, Monash University

The cardiometabolic phenotype of orphan GPR37L1: Not all mice are created equal -#101
Dr Nicola Smith, UNSW Sydney

"Threshold vs mastery": A new way to teach and assess. -#105
Dr Shannan Maisey, UNSW Sydney

Targeting GPCRs for the development of new heart failure therapeutics -#108
Dr Lauren May, Monash University

Understanding the physiological consequences of biased agonism at the GLP-1R -#102
Dr Elva Zhao, Monash University

Skills priorities for a future ready workforce -#106
Prof Kevin Pflieger, University of Western Australia

Bromodomain-containing protein inhibition as a therapeutic strategy in heart failure -#109
Dr Simon Foster, QIMR Berghofer Medical Research Institute

Regulation of GPCR signalling at adrenergic receptor -#103
Prof Walter J Koch, Temple University, Pennsylvania, USA

Decision-making by reflection: An interprofessional experience -#107
Ms Aynsley Peterson, University of Otago, New Zealand

Pharmacological development of new medicines for heart failure -#110
Prof Peter Molenaar, The University of Queensland

Resolving inflammation as an emerging approach to treat vascular complication -#104
Dr Chengxue Helena Qin, Monash University

Panel discussion

Novel approaches to heart preservation during transplantation - Hypothermic Ex Vivo Perfusion -#111
Dr Louise See Hoe, The University of Queensland and The Prince Charles Hospital

2.15 – 2.29

Break

Supported by



Program continued on next page



**APSA-ASCEPT 2022
JOINT CONFERENCE**

**LOCAL AND GLOBAL
PARTNERSHIPS TO
DRIVE INNOVATION
AND IMPACT**

WWW.APSA-ASCEPT2022.COM
#APSA-ASCEPT2022



DATE
Monday 28 November –
Friday 2 December 2022

VENUE
Crown Perth
Western Australia






Tuesday 30 November 2021 | continued 12.00 – 5.40 pm Australian Eastern Daylight Time (AEDT)

2.30 – 3.55 Concurrent 2 oral sessions			
Oral presentations 1: Education Forum Supported by 	Oral presentations 2: Drug Discovery	Oral presentations 3: Cardiovascular	Oral presentations 4: Clinical Pharmacology Supported by 
Co-chairs: Assoc Prof Barbara Kemp-Harper and Dr Hesham Al-Sallami	Co-chairs: Dr Nicholas Hunt and Ms Silke Chalmers	Co-chairs: Dr Michael De Silva and Dr Melissa Reichelt	Co-chairs: Dr Catherine Lucas and Dr Frida Djukiadmodjo
Development of a novel practical class using crickets to demonstrate the pharmacological actions of drugs for third year neuropharmacology students -#112 Dr Nicole Jones, UNSW Sydney	Characterisation of chemokine GPCRs signalling in monocytes using state-of-the-art phosphoproteomics approach -#117 Miss Rina Pokhrel, Monash University	Combined antiplatelet/ anticoagulant drug for cardiac ischemia/reperfusion injury -#122 Dr Laura Bienvenu, Baker Heart and Diabetes Institute	Antidepressant deprescribing recommendations in clinical practice guidelines for depression: Systematic review -#127 Miss Patricia Yee, The University of Sydney
Attendance but not delivery mode correlates with academic performance in a newly developed pharmacology subject -#113 Assoc Prof Elvan Djouma, La Trobe University	The cardiometabolic expression profile of the sweet taste receptor -#118 Miss Mariah Stavrou, UNSW Sydney	Inactivation of the local cardiac renin angiotensin system improves cardiac performance after myocardial infarction -#123 Ms Zunhan Lu, The University of Queensland	A stewardship program to facilitate anticholinergic and sedative medication deprescribing using the Drug Burden Index integrated in Electronic Medical Records -#128 Dr Nashwa Masnoon, The University of Sydney and Royal North Shore Hospital
Using a design thinking approach to develop a large-scale, inter-professional medication safety micro-curriculum -#114 Assoc Prof Kellie Charles, The University of Sydney	Novel targeted nanotheranostic delivery systems for precision therapy of triple negative breast cancer -#119 Dr Pegah Varamini, The University of Sydney	Activation of the Angiotensin II type 2 receptor prevents progression of cardiac fibrosis associated with hypertension and concomitant diabetes -#124 Miss Mandy Li, Monash University	Deprescribing paracetamol in pain conditions: A scoping review -#129 Mr Thomas Patterson, The University of Sydney
Upskilling Teaching Associates: A bespoke Virtual Teaching Associate Training program -#115 Dr Betty Exintaris and Dr Nilushi Karunaratne, Monash University	Afatinib is a novel and effective drug candidate for the treatment of human uveal melanoma -#120 Assoc Prof Fanfan Zhou, The University of Sydney	Targeting formyl peptide receptors as a novel approach to treat hypertension-induced end-organ damage -#125 Mr Jaideep Singh, Monash University	OPTIMIZE: A pragmatic cluster randomized deprescribing trial in primary care -#130 Dr Emily Reeve, University of South Australia
Nimble pharma®: Pandemic pivoting to a synchronous proxy practical class examining new treatments for COVID-19 -#116 Dr Graham Mackay, The University of Melbourne	The adenosine A2B receptor accelerates invasion in aggressive triple negative breast cancer tumour cells -#121 Miss Sandra Sursock, Monash University	Human amniotic epithelial cells reduce brain injury after tissue plasminogen activator therapy in ischemic stroke -#212 Miss Liz Barreto Arce, La Trobe University	Effect of self-monitoring urate on allopurinol adherence -#131 Mr Jian Chan, UNSW Sydney
3.55 – 3.59 Break			
4.00 – 4.30 ASCEPT Early Achievement Award for Women			
Chair: Assoc Prof Danijela Gnjidic, The University of Sydney The development and application of BRET-based assays to characterise molecular pharmacology -#132 Dr Elizabeth KM Johnstone, Harry Perkins Institute of Medical Research and University of Western Australia			
4.30 – 4.55 British Pharmacological Society keynote presentation			
Chair: Prof Kevin Pflieger, University of Western Australia Tackling dementia: From structure to clinic targeting muscarinic receptors -#133 Prof Andrew Tobin, The University of Glasgow, UK			
5.00 – 5.45 Concurrent 3 session			
5.00 – 5.20 Meet the speaker discussion with BPS speaker, Prof Andrew Tobin Facilitator: Prof Kevin Pflieger, University of Western Australia (20 pre-registered participants)	Discussion group: Getting the balance right – equity, diversity and inclusion in symposia Facilitator: Assoc Prof Tina Hinton, The University of Sydney (20 pre-registered participants and repeated on Thurs 2 Dec)		Time to view ePosters and visit the sponsors' portal

Proud Principal Sponsor

ASCEPT Virtual
Annual Scientific Meeting
29 NOV - 2 DEC 2021



Bb Bellberry Limited supporting research and ethics

NATIONAL · PRIVATE · NOT-FOR-PROFIT ·
SPECIALIST HREC PROVIDER

Our core objectives — to improve
welfare of research participants and
the quality, efficiency & effectiveness of
research in Australia.

Bellberry profits are returned to the
research sector.

Join us... bellberry.com.au



Wednesday 1 December 2021 | 11.30 – 6.15 pm Australian Eastern Daylight Time (AEDT)

- #abstract number

9.00 – 11.29 Time to view ePosters and visit the sponsors' portal

10.00 – 11.00 The 55th Annual General Meeting of ASCEPT (via Zoom)

11.30 Commencement of day two presentations

11.30 – 12.40 Poster presentations by award finalists
for Robert Whelan and Neville Percy prizes

Chairs: Dr Nicola Smith, UNSW Sydney and Assoc Prof Kellie Charles, The University of Sydney

Supported by



12.40 – 12.50 Break

12.50 – 1.20 ASCEPT Gillian Shenfield Early Educator Award

Chair: Dr Angela Finch, UNSW Sydney

Skills coaching: An innovative initiative to support professional skill development in pharmacology students - #200

Dr Nilushi Karunaratne, Monash University

1.20 – 1.50 Japanese Pharmacological Society (JPS) keynote presentation

Chair: Assoc Prof Danijela Gnjidic, The University of Sydney

Unbiased and hypothesis-free approaches to studying the brain and its disorders using whole-brain imaging technique
- #201

Prof Hitoshi Hashimoto, Osaka University, Japan



1.50 – 2.10 Concurrent session

Time to view ePosters and visit the sponsors' portal

Meet the speaker discussion with JPS speaker, Prof Hitoshi Hashimoto
Facilitator: Assoc Prof Danijela Gnjidic, The University of Sydney
(20 pre-registered participants)

2.10 – 2.30 Break

Wednesday 1 December 2021 | continued 11.30 – 6.15 pm Australian Eastern Daylight Time (AEDT)

2.30 – 3.55 Concurrent 4 oral sessions			
Oral presentations 5: Urogenital and Gastrointestinal and Toxicology	Oral presentations 6: Drug Discovery	Oral presentations 7: Cardiovascular and Respiratory and Inflammation	Oral presentations 8: Clinical Pharmacology and Drug Disposition and Response
	Supported by  		
Co-chairs: Dr Iris Lim and Dr Jane Carland	Co-chairs: Dr Simon Foster and Dr Elizabeth Johnstone	Co-chairs: Dr Tracey Gaspari and Dr Simone De Luca	Co-chairs: Dr Frank Reimann and Assoc Prof Cornelia Landersdorfer
Gamma-hydroxybutyrate overdose in inner-Sydney Emergency Departments: A retrospective review - #202 Mr Oliver Harris, UNSW Sydney	Structural insights into allosteric modulation of the human glucagon-like peptide-1 receptor - #207 Dr Xin Zhang, Monash University	Human amnion epithelial cells reduce blood pressure and prevent aortic inflammation and collagen expression during experimental hypertension - #126 Dr Quynh Nhu Dinh, La Trobe University	A systematic review of adverse drug reactions or adverse drug events of heart failure treatment in frail older adults - #221 Ms Mai Duong, The University of Sydney
Polypharmacy with high Drug Burden Index (DBI): Association with microbiome and global function in aged mice - #203 Miss Gizem Gemikonakli, The University of Sydney	Ligand-directed G protein coupling and downstream signalling of the GLP-1R - #208 Mr John Azietaku, Monash University	Inhibition of oxidative stress prevents the onset of glucose intolerance associated with cigarette smoking - #213 Dr Stanley Chan, RMIT University	Targeting hypermutable Pseudomonas aeruginosa clinical isolates with inhaled aztreonam and tobramycin dosing regimens in a dynamic in vitro biofilm model - #217 Miss Siobhonne Breen, Monash University
Chloroacetaldehyde, the toxic urinary metabolite of cyclophosphamide, alters urinary bladder function - #204 Ms Eleanor West, Bond University	The importance of a methylene group in the species variability of VU0467154 at the M4 muscarinic receptor - #209 Dr Emma van der Westhuizen, Monash University	Metabolic profiling of mice with deletion of orphan GPCR, GPR37L1 - #214 Ms Margaret Mouat, UNSW Sydney	Polypharmacy with high Drug Burden Index affects physical performance differently in mice of varying age and sex, over 23 hours - #218 Ms Trang Tran, The University of Sydney
In vitro demonstration of herbal exacerbation of paracetamol-induced hepatotoxicity - #205 Ms Susan Britza, The University of Adelaide	Orthosteric or Allosteric: Implications for determining mechanisms of probe dependence - #210 Mr Wessel Burger, Monash University	Influenza A virus induces peri-vascular adipose tissue inflammation and vascular dysfunction in pregnant mice - #215 Mr Osezua Oseghale, RMIT University	Tobacco cessation medications in tobacco smokers receiving treatment for opioid use disorder - #219 Ms Catherine Lobbe, University of New England and The University of Newcastle
Expression and localisation of mas-related G protein-coupled receptors F and D: A novel study in the human colon - #206 Mr Patrick Hawker, UNSW Sydney	Less is more when it comes to allosteric modulation of the M1 muscarinic receptor - #211 Mrs Huong Nguyen, Monash University	Single cell transcriptomic profiling of the hypertensive mouse aorta - #216 Miss Tayla Hughes, La Trobe University	Comparing effects of polypharmacy on inflammatory profiles in older adults and mice: Implications for translational ageing research - #220 Dr Harry Wu, The University of Sydney

3.55 – 4.10 Break

Program continued on next page

ASCEPT, APFP & APSA Joint Congress

1 – 5 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #ascept-apfp-apsa




Supported by:



Wednesday 1 December 2021 | continued 11.30 –6.15 pm Australian Eastern Daylight Time (AEDT)

4.10 – 5.10 Concurrent 5 symposium session

Symposium 4: Finding the keys in the dark: determining the pharmacology of orphan GPCRs	Symposium 5: Preparing health professional graduates for safe and rational prescribing - current and future opportunities	Symposium 6: Advancing adherence management in the clinical setting
		Supported by  BRITISH PHARMACOLOGICAL SOCIETY
Co-chairs: Dr Nicola Smith and Ms Kinjal Patel, UNSW Sydney	Co-chairs: Prof Sarah Hilmer, The University of Sydney and Assoc Prof Matthew Doogue, University of Otago, New Zealand	Chair: Dr Sophie Stocker, The University of Sydney
The orphan GPCR GPR101 contributes to growth hormone secretion via constitutive activation of Gs and Gq/11 - #222 Dr Julien Hanson, University of Liege, Belgium	The National Prescribing Curriculum – supporting confident and rational prescribing by health professional graduates - #226 Clare Weston, NPS MedicineWise	Impact of adherence on HIV, malaria, and TB treatment and prevention - #230 Prof Rada Savic, University of California San Francisco, USA
Orphan GPR146 regulates blood cholesterol levels in humans and mice - #223 Dr Yan Wang, Wuhan University, China	Recent developments with the PSA - application to other disciplines and other countries - #227 Prof Simon Maxwell, University of Edinburgh, Scotland	A decision support tool for the management of adherence in patients with gout - #231 Dr Daniel Wright, University of Otago, New Zealand
Do RAMP and MRAP accessory proteins modulate orphan putative cannabinoid receptors GPR18 and GPR55? - #224 Dr Natasha Grimsey, University of Auckland, New Zealand	The Prescribing Skills Assessment (PSA) - a journey across Australia and New Zealand, its progress, evaluation and future plans - #228 Assoc Prof Claire Harrison, Monash University	Adherence monitoring in medication assisted treatment of opioid dependence - #232 Assoc Prof Bridin Murnion, University of Newcastle
GPR52 and its role in cognition - #225 Dr Greg Stewart, Monash University	A programmatic interprofessional approach to prescribing education: Medication safety as a team sport - #229 Assoc Prof Kellie Charles and Dr Carl Schneider, The University of Sydney	Estimating forgiveness using trials of placebo-substituted active drugs - #233 Prof Dyfrig Hughes, Bangor University, Wales

5.15 – 5.45 British Toxicology Society (BTS) keynote presentation

Chair: Assoc Prof Danijela Gnjidic, The University of Sydney

New perspectives on drug safety and the mitochondria: from toxicological target to personal susceptibility factor - #234

Dr Amy Chadwick, Department of Pharmacology and Therapeutics, The University of Liverpool, UK

5.45 – 6.15 Networking function

Grab a drink and join us for this interactive networking function where you can catch up with your colleagues and make new acquaintances.

Supported by



Thursday 2 December 2021 | 11.30am – 4.45 pm Australian Eastern Daylight Time (AEDT)

-#abstract number

9.00 – 11.59 Time to view posters and visit the sponsors' portal

11.30 – 12.15 Concurrent session 6

Discussion group: Getting the balance right – equity, diversity and inclusion in symposia

Facilitator: Assoc Prof Tina Hinton, The University of Sydney
(20 pre-registered participants. Repeat of session held on Tues 30 Nov).

Time to view ePosters and visit the sponsors' portal

12.15 – 12.30 Break

12.30 – 2.00 Certara New Investigator Award

Chair: Assoc Prof Danijela Gnjidic, The University of Sydney

Novel targets for the treatment of chronic pelvic pain - #300

Dr Luke Grundy, Flinders University

Oral Nanotherapeutic formulations of Insulin - #301

Dr Nicholas Hunt, The University of Sydney

RAMPing up dynamics at G protein coupled receptors - #302

Dr Tracy Josephs, Monash University

Therapeutic Drug Monitoring for Cancer Care - #303


Dr Madele van Dyk, Flinders University

Supported by

CERTARA

2.00 – 2.15 Break

2.15 – 3.55 Concurrent 7 oral sessions

ASCEPT Garth McQueen student oral prize	Oral presentations 9: Pharmacoepidemiology and Clinical Pharmacology Trainee	Oral presentations 10: Neuropharmacology and Respiratory and Inflammation	Oral presentations 11: Clinical Pharmacology and Pharmacogenomics
			Supported by 
Co-chairs: Dr Nicola Smith and Assoc Prof Kellie Charles	Co-chairs: Assoc Prof Gillian Caughey and Dr Nicholas Farinola	Co-chairs: Dr Luke Grundy and Dr Carl White	Co-chairs: Dr Suong Ngo and Mr Sam Mostafa
GPCR-CoINPocket identifies peptide GPCR ligands with novel off-target activity on the β_2 adrenoceptor - #304 Mr Sean So, UNSW Sydney	COVID-19 restrictions and the incidence and prevalence of prescription opioids in Australia - #310 Ms Monica Jung, Monash University	Cigarette smoking is associated with circadian rhythm disruption in mice - #316 Dr Simone De Luca, RMIT University	Exploration of time-dependent clearance associated with busulfan treatment in paediatrics - #322 Ms Rachael Lawson, The University of Queensland
Formyl peptide receptor agonists as novel vasodilators and anti-inflammatories for pulmonary hypertension - #305 Mr William Studley, Monash University	Development of a tool to evaluate medication management guidance provided to carers of people living with dementia at hospital discharge - #311 Dr Mouna Sawan, The University of Sydney	Effect of the ubiquitin E3 ligase NEDD4-1 on P-gp expression, activity and export of Alzheimer's Aβ peptides - #317 Miss Amanda Chai, The University of Sydney	Population pharmacokinetics and exposure-response analyses for allopurinol in patients with gout - #323 Mr Hailemichael Hishe, University of Otago, New Zealand

Program continued on next page

International Congress of Therapeutic Drug Monitoring & Clinical Toxicology



September 2025

Singapore

Thursday 2 December 2021 | continued 11.30 – 4.45 pm Australian Eastern Daylight Time (AEDT)

ASCEPT Garth McQueen student oral prize	Oral presentations 9: Pharmacoeconomics and Clinical Pharmacology Trainee	Oral presentations 10: Neuropharmacology and Respiratory and Inflammation	Oral presentations 11: Clinical Pharmacology and Pharmacogenomics
Opioid deprescribing guidelines: Moving from evidence to practice - #306 Ms Aili Langford, The University of Sydney	Adverse drug reaction-related hospitalisations among people with dementia - #312 Miss Anum Zaidi, University of Tasmania	Novel antibodies targeting dopamine D2 receptor phospho-sites allow evaluation of reported biased agonists - #318 Dr Alastair Keen, Monash University	A population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients - #324 Ms Ranita Kirubakaran, UNSW Sydney
Pharmacological inhibition or genetic deficiency of insulin regulated aminopeptidase (IRAP) protects against UUO-induced renal injury in mice - #307 Miss Sharenia Chelvarajam, Monash University	Pilot study assessing intestinal toxicity in acute self-poisoning using a novel biomarker Intestinal Fatty Acid Binding Protein - #313 Dr Varan Peranathan, Royal Prince Alfred Hospital	Investigating the correlation between genotype and clinical phenotypes of GABAA receptor variants - #319 Mr Tsz Yuen Jonas Lok, The University of Sydney	A Natural Language Processing Machine-Learning Model for the Detection of Adverse Drug Reactions - #325 Miss Julia Chan, Austin Health, The University of Melbourne
Small molecule Drp1 inhibitors for cardioprotection - #308 Ms Ayesha Augusta Rosdah, The University of Melbourne	Efficacy and safety of Vedolizumab in older adults with Inflammatory Bowel Disease: A systematic review and meta-analysis - #315 Dr Justin Baker, Flinders Medical Centre	Habitual cigarette smoke exposure evokes anxiety-like behaviour in mice which is associated with neuroinflammation and oxidative stress of the amygdala - #320 Mrs Rana Alateeq, RMIT University	Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout - #326 Mr Marcel Schulz, UNSW Sydney
Insulin regulated aminopeptidase (IRAP) inhibition attenuates diabetes-induced cardio-renal pathology and vascular dysfunction in mice - #309 Mr Cameron Hollands, Monash University		Apocynin improves working memory impairments in a mouse model of Chronic Obstructive Pulmonary Disease - #321 Miss Alina Akhtar, RMIT University	Pharmacogenomic testing: Perception of clinical utility, and enablers and barriers to adoption in Australian hospitals. - #327 Dr Sophie Stocker, The University of Sydney
3.55 – 4.05 Break			
4.05 – 4.35 RAND Medal Lecture			
Chair: Assoc Prof Danijela Gnjidic, The University of Sydney Prof Christopher Sobey, La Trobe University			
4.35 – 4.45 Meeting close and awards			
Prof Kevin Pflieger, ASCEPT President Elect			

20th World Congress of
Basic and Clinical Pharmacology
#WCP2026 | wcp2026.org